The quest for the holy grail: new antitubercular chemical entities, targets and strategies. Issue 4 (April 2020)

• Record Type: Journal Article
• Authors: Huszár, Stanislav; Chibale, Kelly; Singh, Vinayak
• Is Part Of: Drug discovery today. Volume 25:Issue 4(2020)
• Page Start: 772
• Page End: 780
• Publication Date: 2020-04
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2020.02.003
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: In 2018 1.2 million people died of tuberculosis. The ideal drug candidate should be active against replicating and nonreplicating Mycobacterium tuberculosis . New drug targets such as EfpA, PptT, ClpP, Pks13, DnaN and QcrB have been identified. Tuberculosis drug discovery is advancing with innovative screens. Abstract : Tuberculosis (TB) remains the leading cause of death from an infectious disease worldwide. TB therapy is complicated by the protracted treatment regimens, development of resistance coupled with toxicity and insufficient sterilizing capacity of current drugs. Although considerable progress has been made on establishing a TB drug pipeline, the high attrition rate reinforces the need to continually replenish the pipeline with high-quality leads that act through inhibition of novel targets. In this review, we highlight some of the key advances that have assisted TB drug discovery with novel chemical matter, targets and strategies – to fuel the TB drug pipeline.